511 related articles for article (PubMed ID: 15067119)
1. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
Noren NK; Lu M; Freeman AL; Koolpe M; Pasquale EB
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5583-8. PubMed ID: 15067119
[TBL] [Abstract][Full Text] [Related]
2. Distinct roles of ephrin-B2 forward and EphB4 reverse signaling in endothelial cells.
Hamada K; Oike Y; Ito Y; Maekawa H; Miyata K; Shimomura T; Suda T
Arterioscler Thromb Vasc Biol; 2003 Feb; 23(2):190-7. PubMed ID: 12588758
[TBL] [Abstract][Full Text] [Related]
3. Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand.
Rutkowski R; Mertens-Walker I; Lisle JE; Herington AC; Stephenson SA
Int J Cancer; 2012 Sep; 131(5):E614-24. PubMed ID: 22161689
[TBL] [Abstract][Full Text] [Related]
4. Ephrin-B2 reverse signaling is required for axon pathfinding and cardiac valve formation but not early vascular development.
Cowan CA; Yokoyama N; Saxena A; Chumley MJ; Silvany RE; Baker LA; Srivastava D; Henkemeyer M
Dev Biol; 2004 Jul; 271(2):263-71. PubMed ID: 15223333
[TBL] [Abstract][Full Text] [Related]
5. Ephrin B2 and EphB4 selectively mark arterial and venous vessels in cerebral arteriovenous malformation.
Bai J; Wang YJ; Liu L; Zhao YL
J Int Med Res; 2014 Apr; 42(2):405-15. PubMed ID: 24517927
[TBL] [Abstract][Full Text] [Related]
6. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway.
Noren NK; Foos G; Hauser CA; Pasquale EB
Nat Cell Biol; 2006 Aug; 8(8):815-25. PubMed ID: 16862147
[TBL] [Abstract][Full Text] [Related]
7. Regulation of signaling interactions and receptor endocytosis in growing blood vessels.
Pitulescu ME; Adams RH
Cell Adh Migr; 2014; 8(4):366-77. PubMed ID: 25482636
[TBL] [Abstract][Full Text] [Related]
8. Ligand-Dependent and Ligand-Independent Effects of Ephrin-B2-EphB4 Signaling in Melanoma Metastatic Spine Disease.
Piffko A; Broggini T; Harms C; Adams RH; Vajkoczy P; Czabanka M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360793
[TBL] [Abstract][Full Text] [Related]
9. The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade.
Scehnet JS; Ley EJ; Krasnoperov V; Liu R; Manchanda PK; Sjoberg E; Kostecke AP; Gupta S; Kumar SR; Gill PS
Blood; 2009 Jan; 113(1):254-63. PubMed ID: 18836096
[TBL] [Abstract][Full Text] [Related]
10. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.
Kumar SR; Singh J; Xia G; Krasnoperov V; Hassanieh L; Ley EJ; Scehnet J; Kumar NG; Hawes D; Press MF; Weaver FA; Gill PS
Am J Pathol; 2006 Jul; 169(1):279-93. PubMed ID: 16816380
[TBL] [Abstract][Full Text] [Related]
11. Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor.
Noren NK; Yang NY; Silldorff M; Mutyala R; Pasquale EB
Biochem J; 2009 Aug; 422(3):433-42. PubMed ID: 19552627
[TBL] [Abstract][Full Text] [Related]
12. Ligand-dependent EphB4 activation serves as an anchoring signal in glioma cells.
Kawahara Y; Furuta T; Sabit H; Tamai S; Dong Y; Jiapaer S; Zhang J; Zhang G; Oishi M; Miyashita K; Hayashi Y; Nakada M
Cancer Lett; 2019 May; 449():56-65. PubMed ID: 30776480
[TBL] [Abstract][Full Text] [Related]
13. EphB4 overexpression in B16 melanoma cells affects arterial-venous patterning in tumor angiogenesis.
Huang X; Yamada Y; Kidoya H; Naito H; Nagahama Y; Kong L; Katoh SY; Li WL; Ueno M; Takakura N
Cancer Res; 2007 Oct; 67(20):9800-8. PubMed ID: 17942910
[TBL] [Abstract][Full Text] [Related]
14. Role of ephrin B2 in human retinal endothelial cell proliferation and migration.
Steinle JJ; Meininger CJ; Chowdhury U; Wu G; Granger HJ
Cell Signal; 2003 Nov; 15(11):1011-7. PubMed ID: 14499344
[TBL] [Abstract][Full Text] [Related]
15. EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
Masood R; Kumar SR; Sinha UK; Crowe DL; Krasnoperov V; Reddy RK; Zozulya S; Singh J; Xia G; Broek D; Schönthal AH; Gill PS
Int J Cancer; 2006 Sep; 119(6):1236-48. PubMed ID: 16615113
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of tumor growth and angiogenesis by soluble EphB4.
Martiny-Baron G; Korff T; Schaffner F; Esser N; Eggstein S; Marmé D; Augustin HG
Neoplasia; 2004; 6(3):248-57. PubMed ID: 15153337
[TBL] [Abstract][Full Text] [Related]
17. Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis.
Djokovic D; Trindade A; Gigante J; Badenes M; Silva L; Liu R; Li X; Gong M; Krasnoperov V; Gill PS; Duarte A
BMC Cancer; 2010 Nov; 10():641. PubMed ID: 21092311
[TBL] [Abstract][Full Text] [Related]
18. The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth.
Kertesz N; Krasnoperov V; Reddy R; Leshanski L; Kumar SR; Zozulya S; Gill PS
Blood; 2006 Mar; 107(6):2330-8. PubMed ID: 16322467
[TBL] [Abstract][Full Text] [Related]
19. Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells.
Füller T; Korff T; Kilian A; Dandekar G; Augustin HG
J Cell Sci; 2003 Jun; 116(Pt 12):2461-70. PubMed ID: 12734395
[TBL] [Abstract][Full Text] [Related]
20. Differential protein expression and oncogenic gene network link tyrosine kinase ephrin B4 receptor to aggressive gastric and gastroesophageal junction cancers.
Liersch-Löhn B; Slavova N; Buhr HJ; Bennani-Baiti IM
Int J Cancer; 2016 Mar; 138(5):1220-31. PubMed ID: 26414866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]